Sprint Bioscience: VADA (VRK1) progress support improved sales - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q4 report. Recorded sales improved to SEK 10.9m from SEK 0.3m in 2022, and operating cash flow improved by SEK 12.5m to a cash burn of SEK -2.7m. The main difference is the support from recurring services related to VADA and the VRK1 program. Spring BioScience can also market and negotiate with new potential partners for the DISA, NIMA and NASH programs. Our Base Case ahead of Q4 was SEK 3.2 (Bull SEK 9.1 and Bear SEK 1.0).

Länk till analysen i sin helhet: https://www.redeye.se/research/979031/sprint-bioscience-vada-vrk1-progress-support-improved-sales?utm_source=finwire&utm_medium=RSS